Phase II study of erlotinib for previously treated patients with EGFR wild‑type non‑small‑cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System
Morise, Masahiro, Taniguchi, Hiroyuki, Saka, Hideo, Shindoh, Joe, Suzuki, Ryujiro, Kojima, Eiji, Hase, Tetsunari, Ando, Masahiko, Kondo, Masashi, Saito, Hiroshi, Hasegawa, YoshinoriLanguage:
english
Journal:
Molecular and Clinical Oncology
DOI:
10.3892/mco.2014.354
Date:
July, 2014
File:
PDF, 298 KB
english, 2014